ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Miscellaneous Rheumatic and Inflammatory Diseases"

  • Abstract Number: 1942 • ACR Convergence 2022

    Maybe Silent: Spine Disease in Chronic Recurrent Multifocal Osteomyelitis, Clinical Features, Risk Factors, and Red Flags

    Shima Yasin1, T. Shawn Sato2, Emma Leisinger2, Aleksander Lenert2, Yongdong (Dan) Zhao3 and Polly Ferguson1, 1University of Iowa Carver College of Medicine, Iowa City, IA, 2University of Iowa, Iowa City, IA, 3University of Washington, Redmond, WA

    Background/Purpose: Chronic recurrent multifocal osteomyelitis (CRMO) is a female predominant autoinflammatory bone disease. The average age at disease onset is 9-10 years. The majority have…
  • Abstract Number: 0563 • ACR Convergence 2022

    High-Dimensional Immunophenotyping with Mass Cytometry Reveals Unique Immune Cell Aberrations in Patients with Undiagnosed Inflammatory and Autoimmune Diseases

    Alisa Mueller1, Takanori Sasaki2, Joshua Keegan1, Jennifer Nguyen1, Alec Griffith1, Elizabeth Feig1, Alice Horisberger3, Ye Cao1, Gregory Keras1, Lauren Briere4, Laurel Cobban1, Daimon Simmons1, Juan Pallais1, Jeffrey Sparks2, V. Michael Holers5, Undiagnosed Diseases Network1, David Sweetser4, Joel Krier1, Joseph Loscalzo1, James Lederer1 and Deepak Rao1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Harvard Medical School and Lausanne University Hospital, Boston, MA, 4Massachusetts General Hospital, Boston, MA, 5University of Colorado, Denver, CO

    Background/Purpose: Few tools are available to evaluate the immune dysregulation in patients with severe autoimmune or inflammatory conditions that do not conform to well-defined rheumatologic…
  • Abstract Number: 2243 • ACR Convergence 2022

    Patient Reported Outcomes from a Randomized Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica

    Vibeke Strand1, Jennifer Sloane Lazar2, Michael C Nivens3, Jingdong Chao4, Stefano Fiore5, Angeliki Giannelou6, Lita Araujo7 and Jerome Msihid8, 1Stanford University School of Medicine, Stanford, CA, 2Sanofi, Delray Beach, FL, 3Regeneron Pharmaceuticals, Inc., Tarrytown, NY, NY, 4Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, 5Sanofi, Bridgewater, NJ, 6Regeneron Pharmaceuticals, Inc., Hoboken, NJ, 7Sanofi, Cambridge, MA, 8Sanofi, Chilly-Mazarin, France

    Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in the elderly. The phase 3 SAPHYR trial (NCT03600818) assessed the efficacy and safety of…
  • Abstract Number: 0758 • ACR Convergence 2022

    Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome After Immune Checkpoint Inhibition: A CanRIO Study

    Azin Rouhi1, Shahin Jamal2, Marie Hudson3, Janet Pope4, Janet Roberts5, Alexandra Ladouceur3, Sara Hewitt6 and Carrie Ye1, 1University of Alberta, Edmonton, AB, Canada, 2University of British Columbia, Vancouver, BC, Canada, 3McGill University, Montréal, QC, Canada, 4University of Western Ontario, London, ON, Canada, 5Dalhousie University, Halifax, NS, Canada, 6Western University, London, ON, Canada

    Background/Purpose: Immune checkpoint inhibitors (ICI) have shown great promise in the treatment of different malignancies. The use of ICIs has been associated with toxicities that…
  • Abstract Number: 0771 • ACR Convergence 2022

    The Use of a bDMARD or tsDMARD for the Management of Rheumatic irAE Under Checkpoint Inhibitors: An Observational Study

    Fanny De La Fuente1, Rakiba Belkhir2, Julien Henry3, Chi Duc Nguyen4, Thao Pham5, Vincent GERMAIN6, Pierre-Edouard Gavand7, Céline Labadie1, Claire Brière8, Ambre Lauret8, Thierry Cardon9, Gaël Mouterde10, Isabelle Bonnet11, Léa Rouxel12, Marie Truchetet1, Thierry schaeverbeke13, Christophe Richez14 and Marie Kostine15, 1Bordeaux University Hospital, Bordeaux, France, 2Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, 3Department of Rheumatology, University Paris-Saclay, Hospital Bicêtre, Le Plessis Robinson, Ile-de-France, France, 4Bethune Hospital, Bethune, France, 5Aix-Marseille univ, APHM, Marseille, France, 6Pau Hospital, Rheumatology, Pau, France, Pau, France, 7Rhena Clinic, Strasbourg, France, 8Intercommunal Creteil Hospital, Créteil, France, 9Lille University Hospital, Lille, France, 10Lapeyronie Hospital, Montpellier, France, 11University Paris-Saclay, Hospital Bicêtre, Bicêtre, France, 12Arcachon Hospital, Arcachon, France, 13CHU de Bordeaux, Bordeaux, France, 14Université de Bordeaux, Bordeaux, France, 15Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France

    Background/Purpose: Rheumatic immune related adverse events (irAEs) are observed in about 5 to 10% of cancer patients receiving checkpoint inhibitors (ICIs), with inflammatory arthritis (IA)…
  • Abstract Number: 0776 • ACR Convergence 2022

    Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey

    Sebastian Bruera1, Maria Suarez-Almazor2 and mar Riveiro-Barciela3, 1Baylor College of Medicine, Houston, TX, 2MD Anderson Cancer Center, Houston, TX, 3Hospital Universitari Vall d'Hebron, Barcelona, Spain

    Background/Purpose: The management of inflammatory arthritis related to immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICI) is challenging. Arthritis can become chronic and require…
  • Abstract Number: 0810 • ACR Convergence 2022

    Analysis of Factors Associated with Good Therapeutic Response to Immunosuppressive Drugs in Patients with Non-infectious Uveitis: A Survival Analysis

    María Paula Álvarez Hernández1, Alejandro Gómez Gómez2, Lara Borrego Sanz3, Rosalía Méndez Fernández3, Pedro Arriola Villalobos3, Esperanza Pato Cour4, David Díaz Valle3 and Luis Rodriguez-Rodriguez4, 1Hospital Clínico San Carlos, Madrid, Spain, 2Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, 3Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, 4Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain

    Background/Purpose: Non-infectious uveitis (NIUs) encompass a varied group of inflammatory diseases affecting the uvea and adjacent tissues, with evidence suggesting an immune-mediated cause. A correct…
  • Abstract Number: 0820 • ACR Convergence 2022

    Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study

    Diala Alawneh1, Moustafa Younis2, Bashar Alzghoul2, Christian Ascoli1, Tricha Shivas3, Mary McGowan3, Khaldoon Alawneh4, Divya Patel2, Israel Rubinstein1 and Nadera Sweiss1, 1University of Illinois at Chicago, Chicago, IL, 2University of Florida, Gainesville, FL, 3Foundation for Sarcoidosis Research, Chicago, IL, 4Jordan University of Science and Technology, Irbid, Jordan

    Background/Purpose: Chronic arthropathy is a rare manifestation of sarcoidosis reported in only 0.2% of patients. However, treatment is challenging because no general consensus regarding appropriate…
  • Abstract Number: 1109 • ACR Convergence 2022

    High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease

    Elena Joerns1, David Karp1, Jeffrey Sparks2, Traci Adams1, Una Makris3 and Chad Newton1, 1UT Southwestern, Dallas, TX, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3UT Southwestern Medical Center and Dallas VA, Dallas, TX

    Background/Purpose: Interstitial lung disease (ILD) is a disease of lung parenchyma manifesting with inflammation and fibrosis. Interstitial lung disease (ILD) is a frequent complication of…
  • Abstract Number: 1110 • ACR Convergence 2022

    Solving Sarcoidosis: A Transcriptome-based Meta-analysis of Clinical Sarcoidosis Studies Illustrates Shared Pathophysiology, Identifies Candidate Biomarkers and Suggests a Therapeutic Mechanism of JAK Inhibition

    Ingrid Lindquist1, James T. Rosenbaum2 and Marcia Friedman3, 1Oregon Health and Science University, Portland, OR, 2Legacy Devers Eye Institute, Portland, OR, 3Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR

    Background/Purpose: Sarcoidosis is a systemic, non-caseating granulomatous disease driven by a dysregulated immune response to environmental antigens. A wide range of clinical manifestations coupled with…
  • Abstract Number: 1111 • ACR Convergence 2022

    Sarcoidosis Rates in BCG-Vaccinated and Unvaccinated Young Adults: A Danish Register-Based Study

    Matthew Baker1, Emese Vágó2, Suzanne Tamang3, Erzsébet Horváth-Puhó2 and Henrik Sørensen2, 1Stanford University, Stanford, CA, 2Aarhus University Hospital, Aarhus, Denmark, 3Stanford Center for Population Health Sciences, Redwood City, CA

    Background/Purpose: The inciting factor or antigen exposure that initiates sarcoidosis remains unknown. However, an infectious trigger such as Mycobacterium spp. or Propionibacterium acnes infection may…
  • Abstract Number: 1308 • ACR Convergence 2022

    Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study

    Diala Alawneh1, Moustafa Younis2, Romesa Hassan1, Bashar Alzghoul2, Shiva Arami1, Tricha Shivas3, Mary McGowan3, Khaldoon Alawneh4, Christian Ascoli1 and Nadera Sweiss1, 1University of Illinois at Chicago, Chicago, IL, 2University of Florida, Gainesville, FL, 3Foundation for Sarcoidosis Research, Chicago, IL, 4Jordan University of Science and Technology, Irbid, Jordan

    Background/Purpose: Patients with sarcoidosis are at an increased risk of developing osteoporosis due to the active inflammatory state and chronic corticosteroid use. Proper dosing of…
  • Abstract Number: 1669 • ACR Convergence 2022

    Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis

    Anne Bass1, Noha Abdel-Wahab2, Pankti Reid3, Jeffrey Sparks4, Cassandra Calabrese5, Deanna Jannat-Khah, DrPH, MSPH6, Diviya Rajesh6, Nilasha Ghosh6, Komal Mushtaq7, Farah Al Haj8, Adewunmi Falohun9, Lydia Gedmintas10, Lindsey MacFarlane11, Senada Arabelovic11, Adi Diab2, Ami Shah12, Clifton O. Bingham III13, Karmela Kim Chan6 and Laura C. Cappelli14, 1Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2UT MD Anderson Cancer Center, Houston, TX, 3University of Chicago Medical Center, Chicago, IL, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Cleveland Clinic Foundation, Cleveland Heights, OH, 6Hospital for Special Surgery, New York, NY, 7Cleveland Clinic, Cleveland, OH, 8Sinai Grace Hospital/ Detroit Medical Center, Detroit, MI, 9MD Anderson Cancer Center, Houston, TX, 10Brigham and Women's Hospital, Boston, MA, 11Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 12Johns Hopkins Rheumatology, Baltimore, MD, 13Johns Hopkins University, Baltimore, MD, 14Johns Hopkins School of Medicine, Baltimore, MD

    Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify…
  • Abstract Number: 0439 • ACR Convergence 2021

    Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer

    Amy Cunningham-Bussel1, Jiaqi Wang2, Lauren Prisco3, Lily Martin2, Kathleen Vanni2, Alessandra Zaccardelli2, Mazen Nasrallah4, Lydia Gedmintas2, Lindsey MacFarlane5, Nancy Shadick6, Mark M. Awad7, Osama E. Rahma7, Nicole LeBoeuf8, Ellen Gravallese9 and Jeffrey Sparks2, 1Brigham and Women's, Brookline, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Pound Ridge, MA, 4MGH, Somerville, MA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham & Women's Hospital, Boston, MA, 7Dana-Farber Cancer Institute, Boston, 8Brigham and Women's Hospital, Department of Dermatology, Boston, MA, 9Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: Immune-related adverse events (irAEs) are a frequent and serious complication of immune checkpoint inhibitor (ICI) treatment for cancer, which can resemble primary rheumatic diseases.…
  • Abstract Number: 0621 • ACR Convergence 2021

    Case Series of IgG4-related Disease in African American Patients at Two Large Academic Centers

    Jonathan Thaler1, Sunita Dia2 and Florina Constantinescu2, 1MedStar Georgetown University Hospital, Washington, DC, 2Medstar Washington Hospital Center, Washington, DC

    Background/Purpose: IgG4-related Disease (IgG4-rD) is a fibroinflammatory disease with highly variable manifestations that can be difficult to diagnose. Response to treatment with prednisone and/or rituximab…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology